Clinical Trial Update: Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients [Phase 3]

View source ↗

Summary

A phase 3 trial comparing nivolumab plus ipilimumab versus chemotherapy as first-line treatment in PS 2 or elderly patients with advanced non-small cell lung ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Rennes University Hospital | Conditions: Advanced Non Small Cell Lung Cancer | Phase 3 | Status: COMPLETED